spacer
home > ebr > summer 2018 > natural intelligence looks at ai
PUBLICATIONS
European Biopharmaceutical Review

Natural Intelligence Looks at AI

Artificial intelligence (AI) is the fourth industrial revolution. Machinelearning, Big Data, and basic science have reached a tipping point where the question is not if, but when. Media coverage of AI is abuzz with driverless cars, facial recognition, and data analytics. However, public reception is divided. Is it a positive transformation of the human condition or a brave new world? Nations and industries alike have embraced AI, fearing to be left behind in the race for global competitive advantage.

AI is now being adopted by all the major biopharmaceutical companies at every stage of their pipeline workflows. Industrial and academic research centres and a spate of new startups and investors are all sprinting towards this new reality. Still, the hype and skepticism surrounding biotechnology applications of AI echoes earlier paradigm shifts in the drug discovery high throughput screening, molecular modelling, and rational design. Critics say these never lived up to the promise, yet they continue to play an important role in drug discovery today.

What Is AI?

AI consists of software systems based on the confluence of computing power, large data sets, and models that mimic the understanding of the human brain. They attempt to self-learn from training sets of data and develop the ability to interpret new inputs. They provide reasoned outputs and predictions in new situations. These learning engines are model-free. Cause-and-effect is not as obvious as one might expect in a linear regression or a decision tree. Simultaneously, they achieve a high level of predictive accuracy in datasets that are too large and multidimensional for an individual to handle.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, a graduate of the Harvard Business School, US, a Chinawatcher, and an industry consultant with experience in the biotech and biopharma industry.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Kieran Coulton named new Chairman at ChargePoint Technology

ChargePoint Technology, specialists in contained and sterile powder transfer solutions has announced the appointment of Kieran Coulton as Chairman. Coulton is an accomplished leader in automation and manufacturing with a track record of 36 years in the industry. Having previously served as President Global Industry for GE Power Conversion, Kieran brings with him a wealth of experience and an ability to achieve excellent levels of business growth.
More info >>

White Papers

Migration safe pharmaceutical labels improve patient safety

UPM Raflatac

Labels play an invaluable role on pharmaceutical packages. Pharmaceutical companies should only use labels that meet low-leachability and extraction requirements. Labels that are not migration safe, e.g. create leachable chemical compounds, may fail testing and result in significant launch delays or costly recalls. This white paper presents how pharmaceutical companies can ensure that the final label constructions achieve their business, regulatory and patient safety goals.
More info >>

 
Industry Events

12th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology

8-11 February 2021, Vienna, Austria

In continuation of the very successful scientific meetings in Budapest, Paris, Berlin, Florence, Geneva, Barcelona, Malta, Istanbul, Lisbon, Glasgow and Granada, the 12th PBP World will be held in Vienna from 8-11 Feb 2021. This every two year held conference has gained an ever increasing impact among the pharmaceutical scientists: With up to 1000 submitted abstracts and about 1300 participants it has become a well-established major meeting, attracting scientists from all over the world.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement